Morphine (Chlorhydrate) Renaudin (Morphine Hydrochloride)

Morphine Hydrochloride, the active ingredient in Morphine (Chlorhydrate) Renaudin, is an opioid analgesic presented as a sterile powder for epidural, intracerebroventricular and other parenteral use. It provides potent analgesia for severe acute, postoperative and cancer‑related pain in adult patients.

GNH USA supplies Morphine (Chlorhydrate) Renaudin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use through established global distribution networks.

Morphine Hydrochloride is an opioid analgesic indicated for several severe pain conditions where strong opioid therapy is required.

- Severe acute pain: delivers rapid, high‑intensity analgesia for sudden, intense pain episodes. - Post‑operative pain: provides effective control of pain following major surgical procedures. - Cancer‑related pain: manages persistent pain associated with malignant disease and its treatment. - Chronic severe pain requiring opioid therapy: offers long‑term relief for patients with pain unresponsive to non‑opioid agents.

Morphine Hydrochloride may cause a range of adverse reactions, varying from mild to life‑threatening.

Common Side Effects: - Nausea: feeling of sickness often accompanied by an urge to vomit. - Constipation: reduced bowel movements and hard stools. - Drowsiness: increased sleepiness or reduced alertness. - Dry mouth: decreased salivation leading to a parched feeling.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be fatal. - Severe hypotension: marked drop in blood pressure causing dizziness or fainting. - Anaphylactic reaction: sudden, severe allergic response with rash, swelling, and airway compromise. - Opioid dependence: risk of tolerance, addiction, and withdrawal symptoms with prolonged use.

When prescribing Morphine Hydrochloride, clinicians should observe several safety measures to minimize risk. - Assess pain severity: determine if opioid therapy is appropriate and the lowest effective dose. - Monitor respiratory function: watch for signs of respiratory depression, especially after dose initiation or escalation. - Evaluate hepatic and renal function: adjust dosing in patients with impaired metabolism or excretion. - Avoid concurrent CNS depressants: limit use of benzodiazepines, barbiturates, or alcohol to reduce additive sedation. - Store at controlled room temperature: keep in the original container, protect from moisture and light.

Morphine Hydrochloride can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Respiratory depressants (e.g., benzodiazepines, barbiturates): may cause profound respiratory depression. - MAO inhibitors (e.g., phenelzine, selegiline): can precipitate severe hypertension or serotonin syndrome. - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): increase morphine plasma concentrations and toxicity risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce morphine effectiveness. - Other opioids or opioid‑like agents: additive sedation and respiratory effects. - Alcohol: enhances central nervous system depression and may increase side‑effects.